Literature DB >> 7309718

Increased synthesis of hexacosanoic acid (C23:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).

S Tsuji, T Sano, T Ariga, T Miyatake.   

Abstract

We studied the metabolism of radioactive stearic acid by cultured skin fibroblasts from patients wtih adrenoleukodystrophy (ALD) and its variant, adrenomyeloneuropathy (AMN), to clarify the mechanism of the increased content of very long chain saturated fatty acids in cholesterol esters and sphingolipids, which are known to be the characteristic biochemical changes in ALD and AMN. A substantial amount of hexacosanoic acid (C26 : 0) wa synthesized from stearic acid by ALD and AMN fibroblasts, whereas only a trace amount of hexacosanoic acid was synthesized by control fibroblasts. This indicates that the primary biochemical defect in ALD and AMN may involved the elongation system of very long chain fatty acids.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7309718     DOI: 10.1093/oxfordjournals.jbchem.a133578

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  19 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 4.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

5.  Decreasing serum VLCFA levels in ageing X-ALD female carriers.

Authors:  T J Stradomska; A Tylki-Szymańska
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

Review 6.  Peroxisomal disorders: a newly recognised group of genetic diseases.

Authors:  R B Schutgens; H S Heymans; R J Wanders; H van den Bosch; J M Tager
Journal:  Eur J Pediatr       Date:  1986-02       Impact factor: 3.183

Review 7.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 8.  Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology.

Authors:  Inderjit Singh; Avtar K Singh; Miguel A Contreras
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

Review 9.  X-linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect.

Authors:  R J Wanders; C W van Roermund; W Lageweg; B S Jakobs; R B Schutgens; A A Nijenhuis; J M Tager
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 10.  Very long chain fatty acids in higher animals--a review.

Authors:  A Poulos
Journal:  Lipids       Date:  1995-01       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.